Double transgenic neonatal porcine islets as an alternative source for beta cell replacement therapy

• 成果类型: Article
• 署名作者: Mourad, Nizar I.; Perota, Andrea; Xhema, Daela; Duchi, Roberto; Lagutina, Irina; Galli, Cesare; Gianello, Pierre
• 署名单位: Universite Catholique Louvain
• 刊物名称: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
• ISSN/ISSBN: 0027-11321
• DOI: 10.1073/pnas.2409138121/-/DCSupplemental
• 发表日期: 2024-11-12
• 关键词: insulin-secretion; nonhuman primate; nutrient control; glucose; xenotransplantation; transplantation; acetylcholine; amplification; distinct

摘要

To be clinically efficient, beta cell replacement therapies such as pig islet xenotransplantation must ensure sufficient insulin secretion from grafted islets. While protection from host immune reaction is essential for islet engraftment and their subsequent functioning, intrinsic physiological properties of used cells are also a key factor. We have previously shown that islets with adenoviral- mediated expression of a dipeptidyl peptidase- resistant form of glucagon-like- peptide- 1 (GLP-1) and a constitutively activated form of type muscarinic receptor (M3R) in their beta cells have greatly improved insulin secretory response to glucose stimulation that is otherwise 4 to 10 times lower than human islets. Here, we describe in vitro characterization of the secretory function of pancreatic islets, derived from transgenic pigs expressing the GLP-1M3R cassette under the porcine insulin promoter (InsGLP- 1M3R), and their usage to treat insulin- dependent diabetes in an immunodeficient mouse model. Our results show that InsGLP-1M3R islets isolated from neonatal and adult pigs secrete up to 15- fold more insulin in response glucose stimulation compared to wild- type (WT) islets. They also proved to be more efficient in treating diabetes in a preclinical model as shown by a significantly higher percentage of normoglycemic recipients and higher porcine C- peptide levels up to 9 mo post implantation.